Based on our in vitro characteristic of the rates of adenosine deamination in different cell populations, the low‐dose dCF treatment should be able to exert above anticancer effects, by complete inhibition of the ADA activity in cancer cells and only mild suppression of its activity in endothelial and immune cells, without any toxic effects. Here, ADA is linked to cancer.